Nazia J. Khan

Nazia Khan is an associate in the Corporate Practice Group in the firm's Washington D.C. office.

Areas of Practice

Ms. Khan’s practice focuses on corporate finance and securities laws. Ms. Khan represents underwriters and companies in various industries including technology, cannabis, life sciences, healthcare, food and beverage, transportation and REITs in capital markets transactions. Her experience includes leading both underwriters as well as domestic and foreign companies in public and private corporate finance transactions, including initial public offerings, shelf registrations, registered direct transactions, private investments in public equity (PIPEs), private placements and other securities offerings. In addition, Ms. Khan’s experience includes initial public offerings of SPACs as well as de-SPAC transactions. She also represents publicly held companies with their reporting obligations under the Exchange Act and with NASDAQ, NYSE and other exchange listing and compliance matters including matters involving FINRA.

Experience

Traditional IPOs:

• Represented Immix Biopharma, Inc. in its initial public offering and listing on Nasdaq
• Represented Greenwich LifeSciences, Inc. in its initial public offering and listing on Nasdaq
• Represented Hoth Therapeutics, Inc. in its initial public offering and listing on Nasdaq
• Represented Immuron Limited in its initial public offering and listing on Nasdaq
• Represented Aridis Pharmaceuticals, Inc., in its initial public offering and listing on Nasdaq
• Represented underwriters in an initial public offering and listing on Nasdaq of a company in the rideshare industry
• Represented underwriters in an initial public offering of and listing on Nasdaq of a biotechnology company focused on early cancer screening and detection

SPACs:

• Represented A.G.P./Alliance Global Partners in an initial public offering and listing on NYSE American of Ault Disruptive Technologies Corporation
• Represented A.G.P./Alliance Global Partners in an initial public offering and listing on Nasdaq of Digital Health Acquisition Corp.

Other Transactions:

• Represented Majesco in sale to private equity firm for $729 million.

Honors

New York Metro Rising Stars, Super Lawyers, 2017-2021

Ones to Watch — Corporate Law, Best Lawyers, 2021, 2022

Who's Who in America, 2019

Articles

Corporate and Securities Law Blog Posts

• "SEC Proposes Amendments to Schedule 13 Beneficial Ownership Reporting Requirements," February 24, 2022

• "SEC Amends Definitions of “Accelerated Filer” and “Large Accelerated Filer” and Provides Relief to Small Issuers from Auditor Attestation Requirements," March 18, 2020

• "SEC Administrative Proceedings Against Public Companies for Failure to Remediate Material Weaknesses in Internal Control Over Financial Reporting," February 5, 2019 
• "Expansion of Regulation A to Reporting Companies: Increased Alternatives Now Available to Public Companies Seeking to Raise Capital or for Mergers and Acquisitions," February 1, 2019
• "The Effects of the SEC Shutdown on the Capital Markets," January 18, 2019
• "SEC Expands the Definition of 'Smaller Reporting Company,'" July 12, 2018

Cannabis Law Blog Posts

• "FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products," March 9, 2020

Media Mentions

Memberships

• Board Member, Ms. JD, Mentor
• Leadership Counsel on Legal Diversity